• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

expresspharmaMarch 12, 2021

Tag: Hikma , GSK , Egypt , Tunisia

Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said.

Hikma, which supplies generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, had said in January it was planning to buy those assets.

Previous:Vir, GSK to seek EUA for COVID-19 antibody therapy

Next:Enveric Biosciences acquires licence for Diverse Biotech’s novel molecules

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Dolutegravir GSK 1349572

Dolutegravir GSK 1349572
GSK1265744 (sodium salt)

GSK1265744 (sodium salt)
GSK 1349572

GSK 1349572
Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572)
Dabrafenib(GSK2118436）

Dabrafenib(GSK2118436）
Cabotegravir (GSK744, GSK1265744)

Cabotegravir (GSK744, GSK1265744)
GSK2636771

GSK2636771
Trametinib(GSK1120212)

Trametinib(GSK1120212)
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service